RxDoctor Payments Data

Sally Dye, NP

Acute Care · Fort Worth, TXNPI 1154608032

Payments from drug & device makers

$902in general payments, 2019–2025

Across 31 payments — averaging $29.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$191
  • AstraZeneca$125
  • Penumbra, Inc.$117
  • Medtronic$111
  • Teleflex LLC$108
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$54
  • plus $196 from 9 others

What the payments were for

  • Food & beverage$902100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$902 in reported general payments places this provider in the 65th percentile of 2,323 acute care providers in Texas.

See all acute care providers in Texas

Medicare billing

Part B allowed, 2024
$29,328
Medicare patients
184
Services billed
263

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban73$91,768
JardianceEmpagliflozin25$29,834
Repatha SureclickEvolocumab28$21,837
XareltoRivaroxaban17$16,956
FarxigaDapagliflozin Propanediol13$14,990
Ezetimibe58$1,177
Rosuvastatin Calcium73$1,131
Telmisartan32$1,094
Carvedilol128$928
Amiodarone Hcl18$866
Atorvastatin Calcium69$817
Losartan Potassium50$778
Amlodipine Besylate130$761
Chlorthalidone62$719
Spironolactone81$630

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$12$16,95617 claims
AstraZenecaFarxiga$125$14,99013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,323 acute care providers in Texas.

Other acute care in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →